BrainXell
BrainXell provides iPSC/ESC-derived human neurons to the pharmaceutical industry and other research organizations for drug discovery and toxicity studies. The core technologies of BrainXell, initially developed by Professor Su-Chun Zhang at the University of Wisconsin-Madison, include: (1) directed differentiation of human pluripotent stem cells to subtype-specific neuronal and glial progenitors, (2) expansion of the committed progenitors to large quantities, and (3) rapid maturation of the progenitors to functional neurons and glia. We are also adapting our cell production technologies to a cGMP environment with ability to efficiently produce large numbers of high-purity neural cells.
